Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer

MV Fournier, KJ Martin, PA Kenny, K Xhaja, I Bosch… - Cancer research, 2006 - AACR
MV Fournier, KJ Martin, PA Kenny, K Xhaja, I Bosch, P Yaswen, MJ Bissell
Cancer research, 2006AACR
Nonmalignant human mammary epithelial cells (HMEC) seeded in laminin-rich extracellular
matrix (lrECM) form polarized acini and, in doing so, transit from a disorganized proliferating
state to an organized growth-arrested state. We hypothesized that the gene expression
pattern of organized and growth-arrested HMECs would share similarities with breast tumors
with good prognoses. Using Affymetrix HG-U133A microarrays, we analyzed the expression
of 22,283 gene transcripts in 184 (finite life span) and HMT3522 S1 (immortal nonmalignant) …
Abstract
Nonmalignant human mammary epithelial cells (HMEC) seeded in laminin-rich extracellular matrix (lrECM) form polarized acini and, in doing so, transit from a disorganized proliferating state to an organized growth-arrested state. We hypothesized that the gene expression pattern of organized and growth-arrested HMECs would share similarities with breast tumors with good prognoses. Using Affymetrix HG-U133A microarrays, we analyzed the expression of 22,283 gene transcripts in 184 (finite life span) and HMT3522 S1 (immortal nonmalignant) HMECs on successive days after seeding in a lrECM assay. Both HMECs underwent growth arrest in G0-G1 and differentiated into polarized acini between days 5 and 7. We identified gene expression changes with the same temporal pattern in both lines and examined the expression of these genes in a previously published panel of microarray data for 295 breast cancer samples. We show that genes that are significantly lower in the organized, growth-arrested HMEC than in their proliferating counterparts can be used to classify breast cancer patients into poor and good prognosis groups with high accuracy. This study represents a novel unsupervised approach to identifying breast cancer markers that may be of use clinically. (Cancer Res 2006; 66(14): 7095-102)
AACR